CL2017002420A1 - Detección de lesión cerebral - Google Patents

Detección de lesión cerebral

Info

Publication number
CL2017002420A1
CL2017002420A1 CL2017002420A CL2017002420A CL2017002420A1 CL 2017002420 A1 CL2017002420 A1 CL 2017002420A1 CL 2017002420 A CL2017002420 A CL 2017002420A CL 2017002420 A CL2017002420 A CL 2017002420A CL 2017002420 A1 CL2017002420 A1 CL 2017002420A1
Authority
CL
Chile
Prior art keywords
tbi
brain injury
victims
cte
neuronal damage
Prior art date
Application number
CL2017002420A
Other languages
English (en)
Spanish (es)
Inventor
Sarjubhai A Patel
Thomas F Rau
Original Assignee
The Univ Of Montana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Univ Of Montana filed Critical The Univ Of Montana
Publication of CL2017002420A1 publication Critical patent/CL2017002420A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2017002420A 2015-03-26 2017-09-26 Detección de lesión cerebral CL2017002420A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/669,454 US9605315B2 (en) 2014-03-26 2015-03-26 Detection of traumatic brain injury

Publications (1)

Publication Number Publication Date
CL2017002420A1 true CL2017002420A1 (es) 2018-07-13

Family

ID=56979279

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002420A CL2017002420A1 (es) 2015-03-26 2017-09-26 Detección de lesión cerebral

Country Status (11)

Country Link
US (3) US9605315B2 (enExample)
EP (1) EP3274008B1 (enExample)
JP (1) JP2018518147A (enExample)
CN (1) CN107427614B (enExample)
AU (2) AU2015387481B2 (enExample)
CA (1) CA2976347A1 (enExample)
CL (1) CL2017002420A1 (enExample)
ES (1) ES3014311T3 (enExample)
IL (1) IL253889A0 (enExample)
SG (1) SG11201707332XA (enExample)
WO (1) WO2016153549A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6211511B2 (ja) 2011-04-18 2017-10-11 ディアミール, エルエルシーDiamir, Llc miRNAに基づくユニバーサルスクリーニングテスト(UST)
WO2015073972A1 (en) 2013-11-18 2015-05-21 Diamir, Llc METHODS OF USING mIRNAs FROM BODILY FLUIDS FOR DETECTION AND MONITORING OF PARKINSON'S DISEASE (PD)
EP3377074B1 (en) * 2015-11-18 2024-01-03 Dignity Health Methods of diagnosing post traumatic epilepsy
US10975436B2 (en) 2016-01-05 2021-04-13 Diamir, Llc Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders
GB201603967D0 (en) * 2016-03-08 2016-04-20 Univ Birmingham Biomarkers of traumatic brain injury
US11149313B2 (en) 2016-03-21 2021-10-19 Diamir, Llc Methods of using miRNAs from bodily fluids for detection and differentiation of neurodegenerative diseases
CN108300788B (zh) * 2017-01-13 2021-07-09 中国人民解放军南京军区南京总医院 一种用于检测轻型脑外伤的微小核糖核酸组合及其应用
WO2018175941A1 (en) * 2017-03-23 2018-09-27 Quadrant Biosciences Inc. Analysis and prediction of traumatic brain injury and concusion symptoms
US10781487B2 (en) 2017-07-24 2020-09-22 Diamir, Llc miRNA-based methods for detecting and monitoring aging
EP3803416A4 (en) * 2018-05-31 2022-05-18 Amydis, Inc. COMPOSITIONS AND METHODS FOR DETECTING BRAIN TRAUMA
WO2025039033A1 (en) * 2023-08-21 2025-02-27 Glia Diagnostics Pty Ltd Methods and reagents for diagnosis and/or prognosis of traumatic brain injury
CN118314963B (zh) * 2023-11-13 2024-10-29 中国人民解放军空军特色医学中心 一种基于lasso回归的血小板储存损伤风险预测模型及其构建方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145209A0 (en) * 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
WO2003103583A2 (en) 2002-06-10 2003-12-18 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
WO2009132273A2 (en) * 2008-04-25 2009-10-29 Merck & Co., Inc. Microrna biomarkers of tissue injury
HUE040281T2 (hu) * 2009-09-14 2019-03-28 Banyan Biomarkers Inc Autoantitest markerek traumás agysérülés diagnózisára
WO2011149354A1 (en) * 2010-05-28 2011-12-01 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg Mirnas involved in the blood brain barrier function
TW201231671A (en) * 2011-01-28 2012-08-01 Univ Kaohsiung Medical Method and kit for in vitro diagnosis of atherosclerosis
WO2013032962A2 (en) 2011-08-28 2013-03-07 The Board Of Trustees Of The Leland Stanford Junior University Micro rnas to treat stroke, ischemic brain injury, traumatic brain injury, and neurodegenerative disease
AU2012308092A1 (en) * 2011-09-13 2014-04-17 Commonwealth Scientific And Industrial Research Organisation Detection of viral infection
CA2864606C (en) * 2012-02-15 2021-06-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating and preventing diseases and disorders of the central nervous system
US9101580B2 (en) * 2012-12-18 2015-08-11 Matthew Bennett Compositions and methods for treating traumatic brain injury

Also Published As

Publication number Publication date
AU2021258088A1 (en) 2021-11-25
CN107427614B (zh) 2021-10-15
EP3274008B1 (en) 2024-12-04
US10815529B2 (en) 2020-10-27
US20170268058A1 (en) 2017-09-21
SG11201707332XA (en) 2017-10-30
EP3274008C0 (en) 2024-12-04
ES3014311T3 (en) 2025-04-21
JP2018518147A (ja) 2018-07-12
IL253889A0 (en) 2017-10-31
AU2021258088B2 (en) 2024-11-28
WO2016153549A1 (en) 2016-09-29
US9605315B2 (en) 2017-03-28
US20150344954A1 (en) 2015-12-03
EP3274008A1 (en) 2018-01-31
US20190352716A1 (en) 2019-11-21
EP3274008A4 (en) 2018-10-24
US10202649B2 (en) 2019-02-12
CA2976347A1 (en) 2016-09-29
CN107427614A (zh) 2017-12-01
AU2015387481B2 (en) 2021-08-05
AU2015387481A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
CL2017002420A1 (es) Detección de lesión cerebral
MX2019003474A (es) Metodos mejorados para evaluar el estado de la proteina acidica fibrilar glial (gfap) en muestras de pacientes.
ECSP19044183A (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas
PE20181131A1 (es) COMPOSICIONES DE ARNi PARA LIGANDO 1 DE MUERTE CELULAR PROGRAMADA 1 (PD-L1) Y METODOS DE USO DE LAS MISMAS
EA201792642A1 (ru) Способы диагностики для т-клеточной терапии
MX2019008380A (es) Composiciones de arni contra el componente c5 del complemento y metodos para su uso.
MX2021014709A (es) Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes.
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
WO2017062456A3 (en) Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof
MX2019006177A (es) Metodos para tratar afecciones inflamatorias.
CL2017002825A1 (es) Formulaciones de tpp1 y métodos para tratar la enfermedad de cln2
PH12015502773A1 (en) Methods for treating or preventing opthalmological conditions
MX2015009383A (es) Enfermedades relacionadas con aldehido toxico y tratamiento.
MX2017014532A (es) Vacunas para el tratamiento y prevencion del cancer.
CO2017000346A2 (es) Anticuerpos de unión a protofibrillas aβ
CR20170259A (es) Terapias de envenenamiento y composiciones farmacéuticas, sistemas y equipos relacionados
ECSP14017586A (es) Derivados de tetrahidro-quinazolinona
MX2016010328A (es) Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
CY1122615T1 (el) Θεραπεια με βλαστοκυτταρα σε παθολογιες τουενδομητριου
MX2016010085A (es) Metodos para tratar lesion del cerebro leve.
MX2017003513A (es) Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia.
CY1120139T1 (el) Χρηση κλαδριβινης για αντιμετωπιση οπτικης νευρομυελιτιδας
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
MX2018000528A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
MX376473B (es) Composicion para tratar lesiones cerebrales.